TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16154376

Group type: EXPERIMENTAL
Intervention: Non-closure of peritoneum
Number of subjects: 170

Group type: COMPARATOR
Intervention: Closure of peritoneum
Number of subjects: 170
Study: 12415444

Group type: EXPERIMENTAL
Intervention: HME
Number of subjects: 9

Group type: COMPARATOR
Intervention: HH
Number of subjects: 9
Study: 10730909

Group type: EXPERIMENTAL
Intervention: Terbinafine (Lamisil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Itraconazole (Sporanox)
Number of subjects: 0
Study: 8867004

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1901527

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bruce protocol exercise testing
Number of subjects: 21

Group type: COMPARATOR
Intervention: Less-strenuous, prolonged exercise protocol
Number of subjects: 21
Study: 6281293

Group type: EXPERIMENTAL
Intervention: MK 421 (20 mg orally, twice daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MK 421
Number of subjects: 8
Study: 31968571

Group type: EXPERIMENTAL
Intervention: Oral Mg supplementation (400 mg/day, Mg Oxide)
Number of subjects: 59
Study: 31362715

Group type: EXPERIMENTAL
Intervention: Six-month ART refill in Intervention ACs, meeting twice annually.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SoC) ART refill in SoC ACs, meeting five times annually with two-month ART refills.
Number of subjects: 0
Study: 30594153

Group type: EXPERIMENTAL
Intervention: Arm A (perioperative arm): 2 cycles nab‐paclitaxel (125 mg/m2)/gemcitabine (1000 mg/m2, d1, 8 and 15 of a 28 day‐cycle) followed by tumor surgery followed by 4 cycles nab‐paclitaxel/gemcitabine
Number of subjects: 166

Group type: COMPARATOR
Intervention: Arm B (adjuvant arm): tumor surgery followed by 6 cycles nab‐paclitaxel/gemcitabine
Number of subjects: 166
Study: 26824587

Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement (CTDR)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 209
Study: 24518280

Group type: EXPERIMENTAL
Intervention: LYM-X-SORB™ (LXS) dietary supplements
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo dietary supplements
Number of subjects: 63
Study: 22997994

Group type: EXPERIMENTAL
Intervention: Extensive antiarrhythmic drugs (AADs) therapy (class Ic and III AADs)
Number of subjects: 123

Group type: COMPARATOR
Intervention: One AAD therapy (class Ic or III AADs alone)
Number of subjects: 123
Study: 20678685

Group type: EXPERIMENTAL
Intervention: Test formulation (new generic losartan potassium 50-mg tablet)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Reference formulation (branded losartan potassium 50-mg tablet)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Test formulation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 27
Study: 17363041

Group type: EXPERIMENTAL
Intervention: Percutaneous laser disc decompression
Number of subjects: 0
Study: 15735276

Group type: EXPERIMENTAL
Intervention: Continuous telemetry system linking rural ambulances to a coronary care unit.
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard paramedic treatment (Control).
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Continuous telemetry system.
Number of subjects: 213
Study: 15189574

Group type: EXPERIMENTAL
Intervention: Event frequency manipulation in Study 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Egocentrism in Study 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived frequency of events in Study 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Path analyses
Number of subjects: 0
Study: 10078770

Group type: EXPERIMENTAL
Intervention: 2 exercises
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 8 exercises
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5 exercises
Number of subjects: 15

Group type: COMPARATOR
Intervention: Self-report measurement of compliance
Number of subjects: 15
Study: 7732999

Group type: EXPERIMENTAL
Intervention: Biphasic waveform ICDs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Monophasic waveform ICDs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall implantation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall procedure
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall follow-up
Number of subjects: 27
Study: 2076228

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing sealant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional fissure sealant
Number of subjects: 20
Study: 394267

Group type: EXPERIMENTAL
Intervention: Caerulein (ceruletide) 0.3 mcg/kg intravenously every 4 hours
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no caerulein)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Caerulein (ceruletide)
Number of subjects: 25
Study: 29868778

Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 402

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 402
Study: 26994510

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study: 25222386

Group type: EXPERIMENTAL
Intervention: Medical therapy plus CABG (610 patients)
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Medical therapy alone (602 patients)
Number of subjects: 1212
Study: 22333485

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily
Number of subjects: 8606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8606
Study: 20209409

Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g/100 ml) administered 15 min before the end of surgery and every 6 h for 24 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group received saline administration (100 ml) 15 min before the end of surgery and every 6 h for 24 h
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups received tramadol i.v. via a PCA device
Number of subjects: 50
Study: 18380845

Group type: COMPARATOR
Intervention: Air drying alone (with an air syringe) during the placement of the dentin adhesive on the ground‐flat occlusal dentin surface (Control Group 1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Air drying alone (with an air syringe) during the placement of the dentin adhesive on a standardized MOD cavity (Group 2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Suction drying alone in the standardized MOD cavity (Group 3)
Number of subjects: 15
Study: 16060402

Group type: EXPERIMENTAL
Intervention: Caudal epidural catheterization
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cephalic epidural catheterization
Number of subjects: 45
Study: 11957164

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (15 mg/kg intravenously 1 hour before surgery and 0.3 mg/kg intravenously every 6 hours for 4 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etomidate (to lower cortisol during surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylprednisolone (healthy volunteers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylprednisolone and placebo
Number of subjects: 0
Study: 10410529

Group type: EXPERIMENTAL
Intervention: Surgical treatment for pancreatic endocrine tumors
Number of subjects: 18
Study: 7586430

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate-verapamil (GV) solution
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Papaverine (Pap)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ringer's solution (untreated)
Number of subjects: 36
Study: 2343724

Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms/kg injected after induction under thiopental anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fentanyl 5 micrograms/kg injected after induction under propofol anaesthesia
Number of subjects: 20
Study: 7389482

Group type: EXPERIMENTAL
Intervention: Taurolin (new chemotherapeutic agent)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional antibiotic therapy
Number of subjects: 69
Study: 31122792

Group type: EXPERIMENTAL
Intervention: eReferral (electronic referral)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Control (manual referral)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: eReferral
Number of subjects: 484

Group type: COMPARATOR
Intervention: Control
Number of subjects: 484
Study: 28820950

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training for 24 weeks
Number of subjects: 556

Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 556
Study: 26337448

Group type: EXPERIMENTAL
Intervention: 20 g of red wine grape pomace flour (WGPF) per day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 38
Study: 23295262

Group type: EXPERIMENTAL
Intervention: Intanza 15 μg intradermal vaccine
Number of subjects: 500

Group type: COMPARATOR
Intervention: Inflexal V virosomal adjuvanted intramuscular vaccine
Number of subjects: 500
Study: 22710530

Group type: EXPERIMENTAL
Intervention: Esmolol 1.5mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200mg and Esmolol 1.5mg/kg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo and Normal Saline
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200mg and Normal Saline
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo and Esmolol 1.5mg/kg
Number of subjects: 72
Study: 19366849

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT) with glycemia target of 80-110 mg/dl
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 658

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT) with glycemia target above 215 mg/dl
Number of subjects: 658
Study: 16357619

Group type: EXPERIMENTAL
Intervention: Nadolol plus isosorbide mononitrate (medication group)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Endoscopic treatment (sclerotherapy or ligation) (control group)
Number of subjects: 230
Study: 15210660

Group type: EXPERIMENTAL
Intervention: Morphine sulphate
Number of subjects: 75

Group type: COMPARATOR
Intervention: Phenobarbitone
Number of subjects: 75
Study: 11527789

Group type: EXPERIMENTAL
Intervention: Registry-driven community-based outreach
Number of subjects: 1856

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1856
Study: 9324621

Group type: EXPERIMENTAL
Intervention: Active compression-decompression resuscitation (ACD-CPR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard manual CPR (S-CPR)
Number of subjects: 0
Study: 8129382

Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with irradiation and chemotherapy (HCR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with irradiation and chemotherapy (HCR) with cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-drug combined treatment from other institutes
Number of subjects: 0
Study: 2656902

Group type: COMPARATOR
Intervention: Felodipine extended release (10 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Felodipine plain tablet (10 mg)
Number of subjects: 14
Study: 31437698

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 30
Study: 26595963

Group type: EXPERIMENTAL
Intervention: Combined treatment with yellow turpentine bathtubs and bronchodilators inhalations (atrovent inhalations).
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Monotherapy with yellow turpentine bathtubs alone.
Number of subjects: 89

Group type: COMPARATOR
Intervention: Therapeutic physical exercises and symptomatic medications (control group).
Number of subjects: 89
Study: 23887469

Group type: EXPERIMENTAL
Intervention: Cytoflavin (n=30)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard therapy (Control group, n=17)
Number of subjects: 47
Study: 21912335

Group type: COMPARATOR
Intervention: Sleep-inducing medication (specific agents not detailed), administered over a 2-week period.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) monitoring conducted for three consecutive nights each week, without medication on the first night as a baseline.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Observational assessments (awake, drowsy, or asleep) recorded every 15 minutes during PSG monitoring.
Number of subjects: 40
Study: 19552057

Group type: EXPERIMENTAL
Intervention: 61-points relaxation training (61-PR) for 1 week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cold pressor test (CPT)
Number of subjects: 50
Study: 21977250

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined (losartan 50 mg/ramipril 5 mg/daily)
Number of subjects: 57
Study: 12825849

Group type: EXPERIMENTAL
Intervention: Family history of breast cancer (v.s. no family history)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: High body mass index (> or = 30kg/m2 v.s. < 30kg/m2)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lobular breast cancer histology (v.s. ductal)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Menopausal status, prior hormone replacement therapy, and estrogen/progesterone receptor status of the breast tumors
Number of subjects: 160
Study: 11052901

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8673189

Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine (KET) 4 mg/kg with atropine sulfate 0.01 mg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Combined meperidine, promethazine, and chlorpromazine (MPC)
Number of subjects: 29
Study: 1883251

Group type: EXPERIMENTAL
Intervention: Nalmefene (2.5 mg oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6416476

Group type: EXPERIMENTAL
Intervention: Chlorpropamide (250 mg)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Long term chlorpropamide
Number of subjects: 637

Group type: COMPARATOR
Intervention: Non-insulin dependent diabetics (not on long term chlorpropamide)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Insulin dependent diabetics
Number of subjects: 637

Group type: COMPARATOR
Intervention: Non-diabetics
Number of subjects: 637
Study: 30866834

Group type: EXPERIMENTAL
Intervention: Exergame training combined with daily fish oil supplementation (omega-3 fatty acids)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Exergame training
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Olive oil supplementation
Number of subjects: 58
Study: 27742914

Group type: EXPERIMENTAL
Intervention: Lying flat head position for ≥24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 27555374

Group type: EXPERIMENTAL
Intervention: Prophylactic oral and maxillofacial treatment with 3-monthly dental follow-ups
Number of subjects: 253

Group type: COMPARATOR
Intervention: Standard monitoring and treatment by the patient's dentist
Number of subjects: 253
Study: 23582194

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy (LA)
Number of subjects: 868

Group type: COMPARATOR
Intervention: Open appendicectomy (OA)
Number of subjects: 868
Study: 21762224

Group type: EXPERIMENTAL
Intervention: OC000459 200 mg twice daily
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 20003483

Group type: EXPERIMENTAL
Intervention: Movement Assessment Battery for Children (MABC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MABC subtest ABC‐Ball skills
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clubfoot Assessment Protocol (CAP) item 'one‐leg stand'
Number of subjects: 20
Study: 17508839

Group type: EXPERIMENTAL
Intervention: Active laser therapy with an energy dose of 0.275 J per tender point for nine sessions
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham irradiation (placebo group) for nine sessions
Number of subjects: 39
Study: 15374729

Group type: EXPERIMENTAL
Intervention: 2.5 mg of finasteride every day
Number of subjects: 38

Group type: COMPARATOR
Intervention: 2.5 mg of finasteride every 3 days
Number of subjects: 38
Study: 11435249

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice a day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg twice a day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal subjects (control)
Number of subjects: 45
Study: 9862946

Group type: EXPERIMENTAL
Intervention: HIV-infected adults receiving medical care
Number of subjects: 4042
Study: 8991823

Group type: EXPERIMENTAL
Intervention: Histological and immunohistochemical findings in group A patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Histological findings in group B patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Histological findings in controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immunohistochemical findings in group A patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immunohistochemical findings in group B patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immunological pattern hypothesis
Number of subjects: 20
Study: 2684175

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (120 mg daily dose, 40 mg administered 3 times daily for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 36
Study: 238716

Group type: EXPERIMENTAL
Intervention: Atenolol (Tenormin)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Practolol and placebo
Number of subjects: 11
Study: 30943980

Group type: EXPERIMENTAL
Intervention: CHOhigh + almonds
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CHOhigh
Number of subjects: 24
Study: 28606441

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D therapy (50,000 IU of vitamin D3 intramuscularly monthly for six months)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (distilled water, 0.25mL monthly for six months)
Number of subjects: 85
Study: 25512407

Group type: EXPERIMENTAL
Intervention: Posaconazole i.v. solution (doses: 0, 50, 100, 200, 250, 300 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Posaconazole i.v. solution (100 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vehicle control (0 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Single doses of i.v. posaconazole
Number of subjects: 72
Study: 24498962

Group type: EXPERIMENTAL
Intervention: R&R2MHP cognitive skills program
Number of subjects: 59

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 59
Study: 21449783

Group type: COMPARATOR
Intervention: Placebo plus peginterferon-ribavirin for 44 weeks (Control Group 1)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon-ribavirin for 24 weeks (Group 2)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon-ribavirin for 44 weeks (Group 3)
Number of subjects: 1097
Study: 19894383

Group type: EXPERIMENTAL
Intervention: Compound Zhebei Granules (CZG)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 137
Study: 16380311

Group type: EXPERIMENTAL
Intervention: Psychic healing treatment (exact dosage and duration not specified)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (exact details not specified)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatment and control groups (belief in psychic healing)
Number of subjects: 20
Study: 15697056

Group type: EXPERIMENTAL
Intervention: Anxious Depression (MDD with high anxiety symptoms)
Number of subjects: 1450
Study: 10967896

Group type: EXPERIMENTAL
Intervention: 2nd generation cephalosporin administered on the day of operation and every 8 hours for the next 24 hours; metronidazol for patients operated on trachea and oesophagus.
Number of subjects: 465

Group type: COMPARATOR
Intervention: No prophylactic treatment (before the introduction of the prophylactic regime).
Number of subjects: 465
Study: 9075803

Group type: EXPERIMENTAL
Intervention: 30 microg pramlintide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 microg pramlintide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 microg pramlintide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8417429

Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg/day, single dose)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cefaclor (40 mg/kg/day, 3 divided doses)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 63
Study: 3698066

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg TID
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31712803

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid and 30 mg elemental zinc daily for 6 months
Number of subjects: 2370

Group type: COMPARATOR
Intervention: Matching placebo for 6 months
Number of subjects: 2370
Study: 30351342

Group type: EXPERIMENTAL
Intervention: Health Star Rating (FoPL)
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Daily Intake Guide (FoPL)
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (FoPL)
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Nutrient claim
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: General-level health claim
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Higher-level health claim
Number of subjects: 2069